January 13, 2021 — Interim Phase 1/2a data were published today in the New England Journal of Medicine demonstrating that the Company’s single-dose investigational COVID-19 vaccine candidate (JNJ-78436735) – being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson – provided an immune response that lasted for at least 71 days, the duration of time measured in this study in participants aged 18-55 years. A preview of part of these interim data was posted on medRxiv in September 2020.
Author Archive: AZBio
BIO Announces New Interactive Opportunities to Showcase Your Company
The new Innovation Stage is a must-attend forum provides the best opportunity for leading global innovators, regional economic development groups, patient groups and more to showcase new global biotech insights, build global connections and identify business prospects as a primer to partnering ahead of BIO Digital Week.
Dr. Laurence Hurley Inducted into the National Academy of Inventors
University of Arizona Health Sciences faculty member Laurence Hurley, PhD, professor emeritus in the College of Pharmacy, has been elected as fellow of the National Academy of Inventors (NAI). The NAI Fellows Program highlights academic inventors who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society.Continue reading
Life365 Recognized for Innovation
SCOTTSDALE, AZ — January 12, 2021 — Life365 has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group. Continue reading
CMS Releases Final Rule on Medicare Coverage of Innovative Technology (MCIT)
The CMS rule the establishes a new coverage pathway – MCIT – for breakthrough medical technologies.
Regenesis Biomedical Names Tom Eisiminger, Jr., Chief Executive Officer
Former Vice President of Sales to focus on key value driversContinue reading
Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
- uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis aid pathologists in providing faster, more accurate patient diagnoses in breast cancer
- In combination with the VENTANA DP 200 slide scanner and Roche uPath enterprise software, the new algorithms provide innovative digital pathology solutions to advance personalised healthcare
- Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year.1 About 15 to 20 percent of women diagnosed with breast cancer are HER2 positive.2
State, Partners Opening 24/7 COVID-19 Vaccination Site At State Farm Stadium
Operation Expands Availability With More Arizonans Prioritized For VaccineContinue reading
Economic Impact Payments on their way, visit IRS.gov instead of calling
Looking for your second round of Economic Impact Payment? Learn about eligibility, the process, and how to track your payment.Continue reading
I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic
I Peace’s GMP-grade iPSCs are key to manufacture Avery Therapeutics’ MyCardia™, a proprietary tissue-engineered heart graft developed to treat heart failureContinue reading